Congenital abnormalities and hormones during pregnancy: A clinical review

Teratology

Volumn 22, Issue 3, 1980, Pages 251-270

  Schardein, James L ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; CLOMIFENE; ESTROGEN; ETHISTERONE; GESTAGEN; HORMONE; METHANDRIOL; METHYLTESTOSTERONE; NORETHISTERONE; SEX HORMONE;

ADVERSE DRUG REACTION; CONGENITAL DISORDER; CONGENITAL HEART MALFORMATION; CONGENITAL MALFORMATION; ENDOCRINE SYSTEM; FETUS; HEART; MASCULINIZATION; NEURAL TUBE DEFECT; NEWBORN; PREGNANCY; PRENATAL DRUG EXPOSURE; PSEUDOHERMAPHRODITISM; REVIEW; TERATOGENICITY;

ABNORMALITIES, DRUG-INDUCED; ANDROGENS; CARDIOVASCULAR SYSTEM; CENTRAL NERVOUS SYSTEM; CLOMIPHENE; ESTROGENS; ESTROGENS, SYNTHETIC; FEMALE; HUMAN; INFANT, NEWBORN; MALE; PREGNANCY; PROGESTERONE; PSEUDOHERMAPHRODITISM; VIRILISM;

EID: 0019191862     PISSN: 00403709     EISSN: 10969926     Source Type: Journal    
DOI: 10.1002/tera.1420220302     Document Type: Article

References (208)

1. Clinical and cytogenetic studies in hypospadias
2. Maternal progestins as a possible cause of hypospadias
3. Outcome of pregnancy after clomiphene therapy
4. Are hormonal contraceptives teratogenic?
5. New Zealand Committee on adverse drug reactions. Third annual report
6. Are sex hormones teratogenic?
7. Synthetic sex hormones and infants
8. The outcome of pregnancy in former oral contraceptive users. Royal College of General Practioner's Oral Contraception Study
9. The vater association: Malformations of the male external genitalia
10. An embryo with developmental abnormalities in association with multiple maternal factors
11. Update on the safety and efficacy of clomiphene citrate as a therapeutic agent
12. Failure of large doses of ethinyl estradiol to interfere with early embryonic development in human species
13. Birth defects and oral contraceptives
14. Pregnancy and progeny after use of progestin‐like substances for contraception
15. Anencephaly, ovulation stimulation, subfertility, and illegitimacy
16. A case of cyclopia
17. Congenital abnormalities associated with maternal clomiphene ingestion
18. Anencephaly and clomiphene‐induced pregnancy
19. The use of ethinyl estradiol in pregnancy
20. Female pseudo‐hermaphrodite presenting with bilateral cryptorchidism
21. Effect on the foetus of androgens given during pregnancy
22. Steroids during pregnancy and possible fetal consequences
23. Masculinization of the female infant associated with estrogenic therapy alone during gestation
24. Role of oral contraception in congenital malformations of offspring
25. Progestins and skeletal maturation
26. Cleft lip and palate and pregnancy tests
27. A form of intersexuality
28. Effect of estriol and quinestradiol administered to the pregnant rat on sexual differentiation of the fetus
29. The V.A.C.T.E.R.L. syndrome: A new association of multiple congenital deformities as a possible outcome of hormone administration during pregnancy
30. The effect of provera on the fetus
31. Experimental and clinical chemoteratogenesis
32. Norethindrone‐mestranol as a therapeutic agent
33. Malformation genitale du foetus feminin apres administration d'un nouveau steroide de synthese pendant la grossesse
34. A case of sacrococcygeal teratoma in a newborn after maternal treatment with human gonadotropin
35. The outcome of pregnancy after gonadotrophin therapy
36. Clinical and genetic studies of children born of hormonal contraceptive users
37. Proceedings of the symposium “progesterone, progestins, and fetal development”
38. Place du cyclofenyl parmi les inducteurs de 1′ovulation
39. Oral contraception by norethynodrel. A 3 year field study
40. Habitual abortion treated with 17α‐hydroxyprogesterone caproate
41. Teratogenic drugs‐RCGP survey
42. Birth defects and oral hormone preparations
43. Effects of various sex hormones on excretion of pregnanediol early in pregnancy
44. Does the administration of diethylstilbestrol during pregnancy have therapeutic value?
45. Progestogen therapy in early pregnancy and associated congenital defects
46. Congenital malformations and hormones in pregnancy
47. Virilization and malformation of a female infant
48. Anencephaly and ovulation stimulation
49. Progestin‐induced hermaphroditism: I.Q. and psychosexual identity in a study of 10 girls
50. Clinical uses of 17α‐hydroxy‐6α‐methyl‐progesterone acetate in gynecologic and obstetric practice
51. Bizarre defromities in offspring of users of lysergic acid diethylamide
52. Pseudohermaphroditism: A clinical problem
53. Maternal hormone therapy and congenital heart disease
54. Effect of stilbestrol on pregnancy compared to the effect of a placebo
55. Ovulation stimulation and defects of neural tube closure
56. Masculinization of female infants associated with norethindrone acetate
57. Vaginoplasty technique for female pseudohermaphrodites
58. Nicht‐adrenaler Pseudohermaphroditismus femininus mit vollstandiger Vermann‐lichung des ausseren Genitale
59. Tracheo‐oesophageal fistula associated with hormonal contraception during pregnancy
60. Risks and benefits of the use of hormonal pregnancy test tablets
61. Hormonal pregnancy tests and congenital malformation
62. 46, XY female: Anti‐androgenic effect of oral contraceptive?
63. Syndrome of multiple osseous defects with pretibial dimples
64. The embryology of sexual differentiation in relation to the possible effects of administering steroid hormones during pregnancy
65. Testosterone‐induced female pseudohermaphroditism
66. Induced genital anomalies
67. Seven years of clinical experience with a sequential oral contraceptive
68. Study of norethindrone in contraception
69. First‐trimester exposure to progestagen‐oestrogen and congenital malformations
70. Hormonal pregnancy tests and congenital malformations
71. Maternal drug histories and congenital abnormalities
72. Delay of menstruation with norethindrone, an orally given progestational compound
73. Experimental intersexuality: The effect of antenatal androgens on sexual development of female rats
74. Experimental intersexuality. The effects of estrogens on the antenatal sexual development of the rat
75. Iatrogenic female pseudohermaphroditism
76. The effects of androgens on fetal sexual development. Androgen‐induced female pseudohermaphrodism
77. On the fetal masculinizing action of certain oral progestins
78. Nonadrenal female pseudohermaphroditism after administration of testosterone to mother during pregnancy
79. Outcome of pregnancy after induced ovulation. Follow up of pregnancies and children born after gonadotropin therapy
80. Fetal effects of steroid therapy during pregnancy
81. Birth defects and oestrogens and progesterones in pregnancy
82. Birth defects and female sexual steroids in early pregnancy: A critical review
83. Female pseudohermaphroditism: Report of a case of an infant born of a mother receiving methyltestosterone during pregnancy
84. Masculinization of female fetus, possibly related to administration of progesterone during pregnancy. Report of two cases
85. Cardiovascular birth defects and antenatal exposure to female sex hormones
86. Prenatal sex‐hormone exposure and congenital limb‐reduction defects
87. Nil nocere! Fetal Entwicklungsstorrungen der Genitalorgane nach Hormonbehandlung der Mutter in der Graviditat
88. Norgesterel‐ethinyl estradiol–an oral contraceptive. A clinical study of 725 patients
89. Fetal masculinization with maternal progesterone therapy
90. Congenital malformations. Cleft palate, congenital heart disease, absent tibiae, and polydactyly
91. Zur Frage der hormonaialen Erzeugung fataler Zwittenbildungen beim Menschen
92. Maternal exposure to oral contraceptives and other female sex hormones: Relation of birth defects in a prospectively ascertained cohort of 50,282 pregnancies
93. Athelia and amastia with a dysplastic shoulder girdle. Case report
94. Statistical observation on genital anomalies of newborns following the administration of synthetic progestins to their mothers
95. Statistical observations on genital anomalies of newborns following the administration of progestins to their mothers
96. Abortion: Its prediction and management
97. Hazards of norethindrone therapy during pregnancy
98. Incidence of congenital limb‐reduction deformities
99. Anencephaly, ovulation stimulation, subfertility, and illegitimacy
100. Clomiphene, anenecephaly, and spina bifida
101. The pill and subsequent pregnancies
102. Hormones and limb‐reduction deformities
103. Oral contraceptives and congenital limb‐reduction defects
104. Down's syndrome and oral contraceptive usage
105. Congenital heart disease and prenatal exposure to exogenous sex hormones
106. Case‐control studies on the effect of sex steroids on women and their offspring
107. Congenital cryptorchidism following injection of estrogens in pregnant mice
108. Non‐adrenal female pseudohermaphroditism associated with hormone administration in pregnancy
109. Female hermaphroditism without virilization
110. The genital anomaly associated with prenatal exposure to progestogens
111. Male pseudohermaphrodism. Report of a case, with observations on pathogenesis
112. Birth defects and oral contraceptives
113. The relationship between congenital defects and the use of exogenous progestational ‘contraceptive’ hormones during pregnancy: A 20‐year review
114. Study of the influence of gestanon on the early development of the human embryo
115. Three new synthetic progestins in the treatment of endometriosis
116. A newborn with extensive abnormalities
117. A prospective study of drugs and pregnancy. 3. Hormones
118. Contraceptive treatment with low doses of gestagens
119. Reply to Gal
120. Hormonal pregnancy tests and neural tube malformations
121. Clinical conference–genital abnormaliteis associated with administration of progesteroids to their mothers
122. Results of a study on the possible teratogenic effects of chlormadinone and its possible action on the course of pregnancy
123. Hormone treatment during pregnancy and congenital heart disease
124. Hyperplasia of the interstitial tissue of the embryonal testis after ingestion of hormonal products by the mother
125. Simulated congenital adrenal hyperplasia in a male neonate associated with medroxyprogesterone therapy during pregnancy
126. Is there an embryo‐fetal exogenous sex steroid exposure syndrome (EFESSES)?
127. Female pseudohermaphroditism associated with administration of oral progestin during pregnancy
128. Embryopathy entailed by administration of sex hormones to the mother
129. Absence of upper limbs (amelia) in surviving intrauterine twin after salpingectomy for ectopic pregnancy
130. Cytogenetic studies on women using oral contraceptives and their progeny
131. Clinical application of oral contraceptives
132. Non‐adrenal female pseudohermaphroditism associated with hormone administration in pregnancy
133. Female pseudohermaphroditism due to progestogens
134. Prenatal sex‐hormone exposure and cardiac defects in man
135. Artificially‐induced female pseudoher‐maphroditism
136. Clomiphene and neural tube defects
137. Female non‐adrenal pseudohermaphroditism
138. Examination of teratogenicity of progestogens and/or estrogens by observation of the induced abortuses
139. A syndrome of multiple congenital anomalies associated with teratogenic exposure
140. Preliminary evidence for a possible association between oral contraceptives and birth defects
141. Birth defects and oral contraceptives
142. Can the pill cause birth defects?
143. Congenital abnormalities and first‐trimester exposure to progestogen/oestrogen
144. Exogenous progestogen and estrogen implicated in birth defects
145. Increased prevalence of Down's syndrome (mongolism) among the offspring of women treated with ovulation‐inducing agents
146. Exogenous female hormones and birth defects
147. Hormonal pregnancy tests and congenital malformations
148. Hepatoblastoma in an infant after contraceptive intake during pregnancy
149. Induced pseudo‐hermaphroditism
150. Indirect effect of sex hormones on the fetus
151. Effect of exogenous hormones on the fetus
152. Pregnancy following oral contraceptive therapy
153. Conception control and embryonic development
154. The influence of recent use of an oral contraceptive on early intrauterine development
155. Effects of depomedroxyprogesterone acetate as a contraceptive agent
156. Progestogens and the foetus
157. Fetal malformation not associated with dedendox
158. Clinical use of 17 α‐hydroxyprogesterone 17‐n‐caproate in habitual abortion
159. Hormone therapy during pregnancy: Effects on the fetus and newborn
160. Phallic urethra in female pseudohermaphroditism
161. Prenatal exposure of human foetuses to synthetic progestin and oestrogen affects personality
162. Masculinization of female fetuses in the rat by progestational compounds
163. Long‐term administration of norethindrone in fertility control
164. Chromosomal studies in children born to mothers who previously used hormonal contraceptives
165. Pregnancy and progeny after hormonal contraceptives–genetic studies
166. A retrospective enquiry into possible teratogenic effects of drugs in pregnancy
167. Teratogenesis and maternal progesterone
168. Oral contraception: Potential hazards of hormone therapy during pregnancy
169. Pregnancy outcome following oral contraceptives
170. Ambiguous genitalia in XX male children: Report of two infants
171. The oral‐hormone pregnancy test: Possible association with anencephaly
172. Oral contraceptives and birth defects
173. Pregnancies during oral contraceptive treatment. Swedish experiences
174. Anencephaly and ovulation stimulation
175. Contraceptive use–efficacy study utilizing depo‐provera administered as an intramuscular injection once every 90 days
176. Les dangers pour le produit de conception de medicaments administres a la femme enceinte
177. A recently classified multiple malformative syndrome
178. Hormonal pregnancy tests and spina bifida
179. Double‐blind study of effect of 17‐hydroxyprogesterone caproate on abortion rate
180. Teratogenic drugs and therapeutic agents
181. Human experiences related to adverse drug reactions to the fetus or neonate from some maternally administered drugs
182. Possible relationship between clomiphene and neural tube defects
183. Diethylstilbestrol in the prevention and treatment of complications of pregnancy
184. The problem of teratogenicity
185. Use of human menopausal gonadotrophin for the induction of ovulation
186. Etude teratogene des hormones sexuelles. Premiers resultats d'une enquete epidemiologique portant sur 20,000 femmes
187. A study of the virilizing effect of the progestogens on the female rat fetus
188. Study of the incidence of hypospadias in Rochester, Minnesota, 1940–1970, and a case‐control comparison of possible etiologic factors
189. Habitual abortion. Progesterone‐like hormones for prevention of fetal loss
190. Nebenwirkungen bei hochdosierter Nortestosteronmedikation in der Graviditat
191. Treatment of anovulation with menotropins
192. Fehlbildungen nach Follikelhormonen beim Menschen
193. Birth of an anencephalic fetus following ovulation induction
194. A case of gestagen therapy induced jaundice and female pseudohermaphroditism
195. Drug‐induced female pseudohermaphroditism. A case report of an African baby
196. Masculinization of a female foetus with oestrogenic effect
197. Progestogens and the foetus
198. The problem of human foetal abnormalities with special reference to sex hormones
199. Masculinization of the female fetus associated with norethindrone‐mestranol therapy during pregnancy
200. Vitamin A, pregnancy, and oral contraceptives
201. Masculinization of female fetus due to use of orally given progestins
202. Masculinization of the female fetus
203. Masculinization of female fetus associated with administration of oral and intramuscular progestins during gestation: Nonadrenal pseudohermaphroditism
204. Prenatal exposure to female hormones. Effect on psychosexual development in boys
205. Prenatal exposure to oral contraceptives and transposition of the great vessels in man
206. Uber die Methylandrostendiolbehandlung wahrend einer Schwangerschaft